Practice advisory: The use of felbamate in the treatment of patients with intractable epilepsy

Epilepsia

Volumn 40, Issue 6, 1999, Pages 803-808

  French, J ^a   Smith, M ^a   Faught, E ^a   Brown, L ^a  

^a AMERICAN ACADEMY OF NEUROLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000628324     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1999.tb00784.x     Document Type: Article

References (39)

1. Leppik IE. Felbamate. Epilepsia 1995;36(suppl 2):S66-72.
2. Cruzan S. Suspension of Felbatol use urged. Washington, DC: Press office, Food and Drug Administration, United States Department of Health and Human Services; August 1, 1994.
3. Costin JC. Recommendations for monitoring liver function tests in patients being treated with Felbatol (FBM). Cranbury, NJ: Wallace Laboratories, September 1994.
4. Theodore WH, Raubertas R, Porter RJ, et al. Felbamate: a clinical trial for complex partial seizures. Epilepsia 1991;32:392-7.
5. Leppik IE, Dreifuss FE, Pledger GW, et al. Felbamate for partial seizures: results of a controlled clinical trial. Neurology 1991;41: 1785-9.
6. Bourgeois B, Leppik IE, Sackellares JC, et al. Felbamate: a double-blind controlled trial in patients undergoing presurgical evaluation of partial seizures. Neurology 1993;43:693-6.
7. Devinsky O, Faught RE, Wilder BJ, et al. Efficacy of FBM monotherapy in patients undergoing presurgical evaluation of partial seizures. Epilepsy Res 1995;20:241-6.
8. Faught E, Sachdeo RC, Remler MP, et al. Felbamate monotherapy for partial-onset seizures: an active control trial. Neurology 1993; 43:688-92.
9. Sachdeo R, Kramer LD, Rosenberg A, Sachdeo S. Felbamate monotherapy: controlled trial in patients with partial onset seizures. Ann Neurol 1992;32:386-92.
10. Felbamate Study Group in the Lennox-Gastaut Syndrome. Efficacy of FBM in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 1993;328:29-33.
11. Motte J, Trevathan E, Ardvisson JFV, et al., and the Lamictal Lennox-Gastaut study group. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. N Engl J Med 1997;337:1807-12.
12. Sachdeo RC, Murphy JV, Kamin M. Felbamate in juvenile myoclonic epilepsy [Abstract]. Epilepsia 1992;33(suppl 3):118.
13. Kuzniecky R, Thompson G, Faught E, Kramer L. Felbamate add-on therapy in intractable atypical absence [Abstract]. Epilepsia 1991;32(suppl 3):10.
14. Devinsky O, Kothari M, Rubin R, Mercandetti R, Luciano D. Felbamate for absence seizures [Abstract]. Epilepsia 1992;33 (suppl 3):84.
15. Leroy RF, Castain T. Pilot study of FBM in adult medically refractory primary generalized seizure patients [Abstract]. Epilepsia 1991;32(suppl 3):13.
16. Sachdeo RC, Wagner ML. Felbamate in generalized tonic-clonic seizures [Abstract]. Epilepsia 1991;32(suppl 3):54.
17. Carmant L, Holmes GL, Sawyer S, Rifai N, Anderson J, Mikati MA. Efficacy of FBM in therapy for partial epilepsy in children. J Pediatr 1994;125:481-6.
18. Travaglini MT, Morrison RC, Ackerman BH, Haith LR Jr, Patton ML. Toxic epidermal necrolysis after initiation of FBM therapy. Phrmacotherapy 1995;15:260-4.
19. Pellock JM, Brodie MJ. Felbamate: 1997 update. Epilepsia 1997; 38:1261-9.
20. Kaufman DW, Kelly JP, Anderson T, Harmon DC, Shapiro S. Evaluation of case reports of aplastic anemia among patients treated with FBM. Epilepsia 1997;38:1265-9.
21. Hauser WA, Annegers JF, Elveback LR. Mortality in patients with epilepsy. Epilepsia 1980;21:339-412.
22. Guberman A. Seizure-related injuries and death in adult epilepsy [Abstract]. Can J Neurol Sci 1990;17:256.
23. Vickrey BG, Hays RD, Engel J Jr, et al. Outcome assessment for epilepsy surgery: the impact of measuring health-related quality of life. Ann Neurol 1995;37:158-77.
24. Farrell K. Symptomatic generalized epilepsy and the Lennox-Gastaut syndrome. In: Wyllie E, ed. The treatment of epilepsy, principles and practice, 2nd ed. Baltimore: Williams & Wilkins, 1996:530-9.
25. Plaa GL, Willmore JL. General principles: toxicology. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs, 4th ed. New York: Raven Press, 1995:51-60.
26. Ben-Menachem E. Topiramate. In: Antiepileptic drugs, fourth edition. Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs, 4th ed. New York: Raven Press, 1995:1063-70.
27. Messenheimer J, Ramsay RE, Willmore LJ, et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, crossover trial. Epilepsia 1994;35:113-21.
28. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondary generalized tonic-clonic seizures. N Engl J Med 1985; 313:145-51.
29. Pellock JM. Carbamazepine side effects in children and adults. Epilepsia 1987;28(suppl 3):S64-70.
30. Hart RB, Easton JD. Carbamazepine and hematologic monitoring. Ann Neurol 1982;11:309-12.
31. Dreifuss FE, Langer DH, Moline KA, Maxwell JE. Valproic acid hepatic fatalities II: US experience since 1984. Neurology 1988; 33:201-7.
32. Bryant AE, Dreifuss FE. Valproic acid hepatic fatalities: US experience since 1986. Neurology 1996;46:465-8.
33. Camfield PR. Pancreatitis due to valproic acid. Lancet 1979;1: 1198-9.
34. Coulter DL, Allen RJ. Pancreatitis associated with valproic acid therapy for epilepsy [Letter]. Ann Neurol 1980;7:92.
35. Wyllie E, Wyllie R, Cruse RP, Erenberg G, Rothner AD. Pancreatitis associated with valproic acid therapy. Am J Dis Child 1984; 138:912-4.
36. Yuen AWC. Safety issues. In: Richens A, ed. Clinical update on lamotrigine: a novel antiepileptic agent. Tunbridge Wells: Wells Medical Ltd., 1992:69-75.
37. Makin AJ, Fitt S, Williams R. Fulminant hepatic failure induced by lamotrigine [Letter]. BMJ 1995;311:292.
38. Schaub JEM, Williamson PJ, Barnes EW, Trewby PN. Multisystem adverse reaction to lamotrigine [Letter]. Lancet 1994;344:81.
39. Wyler AR. Corpus callosotomy. In: Wyllie E, ed. The treatment of epilepsy, principles and practice, 2nd ed. Baltimore: Williams & Wilkins, 1996:1097-102.